Understanding CAR T-Cell Therapy in Malignant Mesothelioma
One of the new therapies for mesothelioma is called antigen receptor T-cell therapy. It gives promise to malignant mesothelioma patients. This unique therapy has recently shown that it works in phase I clinical trials. A new report from French scientists details the current state of this therapy. This therapy has only been tested in a highly selected patient population. And it requires highly complex engineering. Yet, the treatment therapy shows promise. Adapting CAR T-Cell Therapy to Mesothelioma Malignant pleural and peritoneal mesothelioma are rare and aggressive cancers. They have had limited treatment options with moderate survival benefits. And all treatments have an impaired quality of life for a very long period. A chemotherapy drug combination known as cisplatin–pemetrexed has been … Continue reading Understanding CAR T-Cell Therapy in Malignant Mesothelioma
Maximizes Your Immune Cell Response with High-Intensity Exercise
There is an increasing role of high-intensity exercise training in cancer care. Evidence suggests that exercise can reduce side effects of treatment. And it has the added benefits of improving physical functioning and quality of life. Exercise leads to an increase of adrenalin, which also triggers a patient’s natural immune response. This can alter the tumor microenvironment and lead to reduced tumor growth. New data suggest that exercise could improve immune responses against cancer cells. It works by increasing immune cell infiltration to the tumor. And it may have an impact on disease progression. A new clinical trial has been initiated. It will investigate if high-intensity exercise can benefit patients with lung cancer. Can adrenalin mobilize and increase the infiltration … Continue reading Maximizes Your Immune Cell Response with High-Intensity Exercise
Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy
A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural mesothelioma is an aggressive cancer that affects older adults. Mesothelioma patients often have other comorbidities making real-world treatment decisions challenging. The first was by choice of first-line chemotherapy. The second was the physician’s choice of second-line chemotherapy versus immunotherapy. And the third was by the physician’s choice of use of maintenance therapy. Physician’s Choice of First-Line Chemotherapy Drugs This is the largest real-world study of U.S. patients diagnosed with mesothelioma. Scientists analyzed physicians’ choice of first-line chemotherapy, second-line therapy, and maintenance therapy. In the first-line chemotherapy analysis, there was no significant difference in patient survival. As of this writing, the only … Continue reading First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy
Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment
Immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. Malignant pleural mesothelioma is an aggressive disease. Asbestos exposure has led to globally poor outcomes. While mesothelioma is an uncommon disease, its occurrence is increasing worldwide. Immunotherapy drugs have the potential to make chemotherapy more effective for mesothelioma patients. Researchers theorized immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. The latest results in Molecular and Clinical Oncology suggest that they were right. The findings could have implications for people around the world with mesothelioma. First- and Second-Line Treatment Options for Mesothelioma Patients affected by mesothelioma have a very severe prognosis. Mesothelioma develops after three to four decades after initial exposure to asbestos. For years, the main … Continue reading Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment
Bevacizumab: An Immune Therapy in Mesothelioma Treatment
Bevacizumab, an immune therapy, enhances the immune system to target cancer cells. Historically, chemotherapy drugs were considered the standard treatment. But, a new study highlights bevacizumab, an immune therapy. It can now be considered in combination with mesothelioma treatments where accessible. Chemotherapy has been a popular treatment therapy. Cytotoxic chemotherapy uses anti-cancer (cytotoxic) drugs to destroy cancer cells. It results in a modest improvement in patient survival. But toxicity limits the eligible patient population. Targeted Chemotherapy Agents Immunotherapies are now playing a greater role in the treatment of many cancers. The last decade has presented a paradigm shift. There has been a change in the way we understand the relationship between the immune system and cancer progression. Several targeted agents … Continue reading Bevacizumab: An Immune Therapy in Mesothelioma Treatment
Celiac Disease May Be a Little-Known Complication of Mesothelioma Immunotherapy
A new French case report shines a spotlight on a little-known potential complication of mesothelioma immunotherapy: celiac disease. Celiac disease is a chronic digestive and immune disorder brought on by sensitivity to gluten. Over time, celiac disease damages the small intestine causing long-lasting digestive problems. It can prevent patients from getting the nutrients they need to stay healthy. The new case report appears in Frontiers in Immunology. It details the case of a 70-year-old man who developed celiac disease after treatment with nivolumab. The case suggests that celiac disease may be an underrecognized side effect of mesothelioma immunotherapy. It is a reminder for mesothelioma patients and doctors to pay close attention to digestive problems after treatment. Stimulating the Immune System … Continue reading Celiac Disease May Be a Little-Known Complication of Mesothelioma Immunotherapy
“Remodeling” Mesothelioma Cells May Improve Responsiveness to Immunotherapy
Italian researchers are experimenting with the idea of remodeling mesothelioma cells from the inside out to improve their responsiveness to immunotherapy. Malignant mesothelioma is highly resistant to standard cancer treatments. Immunotherapy is widely considered to be one of the most hopeful new approaches to this cancer. But this approach works better for some people than it does for others. The difference may lie in the genes. Scientists at University Hospital of Siena believe that manipulating the gene expression of mesothelioma cells could be the key to bolstering responsiveness to immunotherapy. Mesothelioma, Genetics, and Responsiveness to Immunotherapy Immunotherapy is a method of treating disease by using the body’s natural immune response. This can mean trying to attract more immune cells to … Continue reading “Remodeling” Mesothelioma Cells May Improve Responsiveness to Immunotherapy
Expert Says Malignant Mesothelioma Research ‘Turned a Corner’ in 2021
An internationally-known mesothelioma specialist says 2021 has been one of the best years yet for malignant mesothelioma research, giving patients and their families more reason than ever to be hopeful. Hedy Lee Kindler, MD, is Director of the University of Chicago Medical Center’s Mesothelioma Program. In a commentary in JCO Oncology Practice, Dr. Kindler says the outlook for mesothelioma sufferers this year is “far brighter than it has been for a very long time.” Dr. Kindler points to several recent advances in malignant mesothelioma research and treatment as reasons for optimism. The FDA approved the second systemic therapy for mesothelioma in late 2020. This year saw five positive mesothelioma clinical trials. Kindler says these advances suggest that the future may … Continue reading Expert Says Malignant Mesothelioma Research ‘Turned a Corner’ in 2021
Chemotherapy Still Good First-Line Option for Unresectable Epithelioid Mesothelioma
A top mesothelioma expert says chemotherapy may still be the best first-line treatment for unresectable epithelioid mesothelioma, even though immunotherapy is an increasingly popular option. Chemotherapy has been the primary way to treat mesothelioma since 2004. This is when the FDA approved the drug Alimta (pemetrexed). Alimta remained the only systemic treatment for asbestos cancer until 2020. In 2020, the FDA approved a combination of the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo). But Dean Fennell, PhD, of the UK’s University of Leicester says chemotherapy is still a good choice for many unresectable epithelioid mesothelioma cases. A Better Version of Chemotherapy? Epithelioid mesothelioma is the most common subtype. It is also the most responsive to treatment. For the healthiest patients, … Continue reading Chemotherapy Still Good First-Line Option for Unresectable Epithelioid Mesothelioma
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!